NASDAQ:EQRX EQRx (EQRX) Stock Forecast, Price & News $1.83 +0.01 (+0.55%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.76▼$1.8550-Day Range$1.61▼$1.9652-Week Range$1.58▼$6.05Volume1.36 million shsAverage Volume1.51 million shsMarket Capitalization$891.87 millionP/E RatioN/ADividend YieldN/APrice Target$4.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media EQRx MarketRank™ ForecastAnalyst RatingHold1.67 Rating ScoreUpside/Downside149.5% Upside$4.57 Price TargetShort InterestBearish7.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.57) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector523rd out of 983 stocksPharmaceutical Preparations Industry252nd out of 486 stocks 2.8 Analyst's Opinion Consensus RatingEQRx has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.57, EQRx has a forecasted upside of 149.5% from its current price of $1.83.Amount of Analyst CoverageEQRx has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.01% of the float of EQRx has been sold short.Short Interest Ratio / Days to CoverEQRx has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in EQRx has recently decreased by 3.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEQRx does not currently pay a dividend.Dividend GrowthEQRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EQRX. Previous Next 3.3 News and Social Media Coverage News SentimentEQRx has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for EQRx this week, compared to 1 article on an average week.MarketBeat Follows1 people have added EQRx to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EQRx insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of EQRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.61% of the stock of EQRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for EQRx are expected to decrease in the coming year, from ($0.57) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EQRx is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EQRx is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEQRx has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About EQRx (NASDAQ:EQRX) StockEQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.Read More Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address EQRX Stock News HeadlinesJune 2, 2023 | americanbankingnews.comEQRx (NASDAQ:EQRX) Stock Price Up 3.6%May 25, 2023 | americanbankingnews.comEQRx (NASDAQ:EQRX) Trading Down 4.9%June 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 19, 2023 | seekingalpha.comCStone Breaks Up With Drugs Partner As U.S. Rollout StallsMay 10, 2023 | msn.comThe World Has Its Way With EQRxMay 9, 2023 | finance.yahoo.comQ1 2023 EQRx Inc Earnings CallMay 9, 2023 | markets.businessinsider.comEQRx Announces Massive Strategic Reset, Slashes Pipeline & WorkforceMay 8, 2023 | seekingalpha.comEQRx, Inc. (EQRX) Q1 2023 Earnings Call TranscriptJune 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 8, 2023 | msn.comEQRx GAAP EPS of -$0.17 misses by $0.03May 8, 2023 | finance.yahoo.comEQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial ResultsMay 8, 2023 | finance.yahoo.comEQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial ResultsMay 7, 2023 | americanbankingnews.comEQRx (EQRX) Scheduled to Post Quarterly Earnings on MondayMay 5, 2023 | msn.comEarnings Outlook For EQRxApril 27, 2023 | finance.yahoo.comEQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023April 21, 2023 | technews.tmcnet.comEQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of ShareholdersApril 12, 2023 | americanbankingnews.comEQRx (NASDAQ:EQRX) Trading Down 4.8%April 5, 2023 | msn.comVBI Vaccines (VBIV) Down 53% on Initiating Restructuring PlansMarch 24, 2023 | americanbankingnews.comEQRx (NASDAQ:EQRX) Stock Price Down 3.3%March 13, 2023 | marketwatch.comEQRx Chief Financial Officer Jami Rubin Resigns >EQRXFebruary 24, 2023 | bizjournals.comCompany founded to make 'radically' cheap drugs lays off 66February 23, 2023 | finance.yahoo.comEQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate ProgressFebruary 23, 2023 | msn.comEQRx GAAP EPS of -$0.05 beats by $0.14February 23, 2023 | finance.yahoo.comEQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate ProgressFebruary 13, 2023 | msn.comEQRx, Inc. (EQRX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowJanuary 3, 2023 | finance.yahoo.comEQRx to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | insidermonkey.com5 Best Affordable Stocks to Buy Under $5See More Headlines EQRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EQRX Company Calendar Today6/03/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EQRX CUSIPN/A CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.57 High Stock Price Forecast$5.50 Low Stock Price Forecast$3.20 Forecasted Upside/Downside+149.5%Consensus RatingHold Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.03% Return on Assets-17.72% Debt Debt-to-Equity RatioN/A Current Ratio22.63 Quick Ratio22.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.70 per share Price / Book0.68Miscellaneous Outstanding Shares487,360,000Free Float398,172,000Market Cap$891.87 million OptionableOptionable Beta0.57 Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Founder & Exec. Chairman of Board of Directors Comp: $858.22kMs. Melanie I. Nallicheri (Age 54)CEO & Director Comp: $832kMs. Jamilu E. Rubin (Age 59)Chief Financial Officer Comp: $479.57kDr. Eric E. Hedrick M.D. (Age 58)Chief Physician Exec. Comp: $575.1kMr. Robert Forrester LL.B. (Age 59)Co-Founder & Advisor Dr. Peter B. Bach M.D. (Age 58)MAPP, Co-Founder & Advisor Sir Andrew Dillon CBECo-Founder & AdvisorMr. Daniel Hoey (Age 56)Chief of Technical Operations Ms. Dina Ciarimboli J.D. (Age 54)Gen. Counsel & Corp. Sec. Ms. Rona Anhalt (Age 58)Chief People Officer More ExecutivesKey CompetitorsMersana TherapeuticsNASDAQ:MRSNCogent BiosciencesNASDAQ:COGTANI PharmaceuticalsNASDAQ:ANIPPharming GroupNASDAQ:PHARCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCBought 29,900 shares on 6/1/2023Ownership: 0.006%ProShare Advisors LLCSold 8,728 shares on 5/26/2023Ownership: 0.012%Ameriprise Financial Inc.Bought 294,669 shares on 5/22/2023Ownership: 0.060%JPMorgan Chase & Co.Bought 67,145 shares on 5/18/2023Ownership: 0.340%New York State Common Retirement FundSold 46,100 shares on 5/18/2023Ownership: 0.017%View All Institutional Transactions EQRX Stock - Frequently Asked Questions Should I buy or sell EQRx stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EQRx in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EQRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EQRX, but not buy additional shares or sell existing shares. View EQRX analyst ratings or view top-rated stocks. What is EQRx's stock price forecast for 2023? 3 equities research analysts have issued twelve-month price targets for EQRx's stock. Their EQRX share price forecasts range from $3.20 to $5.50. On average, they anticipate the company's share price to reach $4.57 in the next year. This suggests a possible upside of 149.5% from the stock's current price. View analysts price targets for EQRX or view top-rated stocks among Wall Street analysts. How have EQRX shares performed in 2023? EQRx's stock was trading at $2.46 on January 1st, 2023. Since then, EQRX stock has decreased by 25.6% and is now trading at $1.83. View the best growth stocks for 2023 here. When is EQRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our EQRX earnings forecast. What ETFs hold EQRx's stock? ETFs with the largest weight of EQRx (NASDAQ:EQRX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB). What is EQRx's stock symbol? EQRx trades on the NASDAQ under the ticker symbol "EQRX." Who are EQRx's major shareholders? EQRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (5.05%), Softbank Group CORP. (4.44%), BlackRock Inc. (3.28%), State Street Corp (2.90%), Arboretum Ventures LLC (2.85%) and Geode Capital Management LLC (0.90%). How do I buy shares of EQRx? Shares of EQRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is EQRx's stock price today? One share of EQRX stock can currently be purchased for approximately $1.83. How much money does EQRx make? EQRx (NASDAQ:EQRX) has a market capitalization of $891.87 million. The company earns $-169,090,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. How many employees does EQRx have? The company employs 240 workers across the globe. How can I contact EQRx? EQRx's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is iii.cmlifesciencesspac.com. The company can be reached via phone at 617-315-2255 or via email at investors@eqrx.com. This page (NASDAQ:EQRX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.